Eli Lilly will invest $450 million in a North Carolina manufacturing plant to meet growing demand for its diabetes drugs Mounjaro and Trulicity, the company said Tuesday.
The investment in the Research Triangle Park plant will expand filling, device assembly and packaging capacity to help the Indiana-based drugmaker double production of the injectable drugs by the end of 2023.
The increased production of Trulicity and of Mounjaro, Lilly’s newest diabetes drug, comes as rival Novo Nordisk has struggled to manufacture enough of its obesity drug Wegovy, which comes from a similar class of blood-sugar lowering drugs as Lilly’s medicines. Lilly could receive an expanded approval for Mounjaro as a weight-loss treatment later this year.
